bay-k-8644 has been researched along with Autoimmune Diabetes in 3 studies
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester: A dihydropyridine derivative, which, in contrast to NIFEDIPINE, functions as a calcium channel agonist. The compound facilitates Ca2+ influx through partially activated voltage-dependent Ca2+ channels, thereby causing vasoconstrictor and positive inotropic effects. It is used primarily as a research tool.
Bay-K-8644 : A racemate comprising equimolar amounts of (R)- and (S)-Bay-K-8644
methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate : A pentasubstituted dihydropyridine carrying methoxycarbonyl, 2-(trifluoromethyl)phenyl and nitro substituents at positions 3, 4 and 5 respectively as well as two methyl substituents at positions 2 and 6.
Excerpt | Relevance | Reference |
---|---|---|
"Serum from patients with IDDM increased L-type calcium channel activity of insulin-producing cells and of GH3 cells derived from a pituitary tumor." | 1.29 | Increased activity of L-type Ca2+ channels exposed to serum from patients with type I diabetes. ( Ammälä, C; Bokvist, K; Dypbukt, J; Hallberg, A; Juntti-Berggren, L; Larsson, O; Nicotera, P; Orrenius, S; Rorsman, P; Wåhlander, K, 1993) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jackson, MW | 2 |
Gordon, TP | 2 |
Wan, EC | 1 |
Juntti-Berggren, L | 1 |
Larsson, O | 1 |
Rorsman, P | 1 |
Ammälä, C | 1 |
Bokvist, K | 1 |
Wåhlander, K | 1 |
Nicotera, P | 1 |
Dypbukt, J | 1 |
Orrenius, S | 1 |
Hallberg, A | 1 |
3 other studies available for bay-k-8644 and Autoimmune Diabetes
Article | Year |
---|---|
A novel impedance-based cellular assay for the detection of anti-calcium channel autoantibodies in type 1 diabetes.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2010 |
Autoantibody-mediated bladder dysfunction in type 1 diabetes.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2007 |
Increased activity of L-type Ca2+ channels exposed to serum from patients with type I diabetes.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1993 |